BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Fish and Richardson
US Army

Generated: December 16, 2017

DrugPatentWatch Database Preview

Details for Patent: RE42461

« Back to Dashboard

Which drugs does patent RE42461 protect, and when does it expire?

Patent RE42461 protects LIPTRUZET, VYTORIN, and ZETIA, and is included in three NDAs. There have been zero Paragraph IV challenges on Vytorin and Zetia

Protection for LIPTRUZET has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

Summary for Patent: RE42461

Title:Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
Abstract: Hydroxy-substituted azetidinone hypocholesterolemic agents of the formula ##STR00001## or a pharmaceutically acceptable salt thereof, wherein: Ar.sup.1 and Ar.sup.2 are aryl or R.sup.4-substituted aryl; Ar.sup.3 is aryl or R.sup.5-substituted aryl; X, Y and Z are --CH.sub.2--, --CH(lower alkyl)-- or --C(dilower alkyl)--; R and R.sup.2 are --OR.sup.6, --O(CO)R.sup.6, --O(CO)OR.sup.9 or --O(CO)NR.sup.6R.sup.7; R.sup.1 and R.sup.3 are H or lower alkyl; q is 0 or 1; r is 0 or 1; m, n and p are 0-4; provided that at least one of q and r is 1, and the sum of m, n, p, q and r is 1-6; and provided that when p is O and r is 1, the sum of m, q and n is 1-5; R.sup.4 is selected from lower alkyl, R.sub.5, --CF.sub.3, --CN, --NO.sub.2 and halogen R.sup.5 is selected from --OR.sup.6, --O(CO)R.sup.6, --O(CO)OR.sup.9, --O(CH.sub.2).sub.1-5OR.sup.6, --O(CO)NR.sup.6R.sup.7, --NR.sub.6R.sup.7, --NR.sup.6(CO)R.sup.7, --NR.sup.6(CO)OR.sup.9, --NR.sup.6(CO)NR.sup.7R.sup.8, --NR.sup.6SO.sub.2R.sup.9, --COOR.sup.6, --CONR.sup.6R.sup.7, --COR.sup.6, --SO.sub.2NR.sup.6R.sup.7, S(O).sub.0-2R.sup.9, --O(CH.sub.2).sub.1-10--COOR.sup.6, --O(CH.sub.2).sub.1-10CON.sup.6R.sup.7, --(lower alkylene)COOR.sup.6 and --CH.dbd.CH--COOR.sup.6; R.sup.6, R.sup.7 and R.sup.8 are H, lower alkyl or aryl-substituted Ic R.sup.9 is lower alkyl, aryl or aryl-substituted lower alkyl; are disclosed, as well as a method of lowering serum cholesterol by administering said compounds, alone or in combination with a cholesterol biosynthesis inhibitor, pharmaceutical compositions containing them; and a process for preparing them.
Inventor(s): Rosenblum; Stuart B. (West Orange, NJ), Dugar; Sundeep (San Jose, CA), Burnett; Duane A. (Bernardsville, NJ), Clader; John W. (Milton, VT), McKittrick; Brian A. (New Vernon, NJ)
Assignee: Schering Corporation (Kenilworth, NJ)
Application Number:12/797,341
Patent Claim Types:
see list of patent claims
Compound; Use; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Merck Sharp DohmeLIPTRUZETatorvastatin calcium; ezetimibeTABLET;ORAL200153-001May 3, 2013DISCNYesNo► Subscribe► SubscribeY► Subscribe
Merck Sharp DohmeLIPTRUZETatorvastatin calcium; ezetimibeTABLET;ORAL200153-002May 3, 2013DISCNYesNo► Subscribe► SubscribeY► Subscribe
Merck Sharp DohmeLIPTRUZETatorvastatin calcium; ezetimibeTABLET;ORAL200153-003May 3, 2013DISCNYesNo► Subscribe► SubscribeY► Subscribe
Merck Sharp DohmeLIPTRUZETatorvastatin calcium; ezetimibeTABLET;ORAL200153-004May 3, 2013DISCNYesNo► Subscribe► SubscribeY► Subscribe
Msd IntlVYTORINezetimibe; simvastatinTABLET;ORAL021687-001Jul 23, 2004ABRXYesNo► Subscribe► SubscribeY► Subscribe
Msd IntlVYTORINezetimibe; simvastatinTABLET;ORAL021687-002Jul 23, 2004ABRXYesNo► Subscribe► SubscribeY► Subscribe
Msd IntlVYTORINezetimibe; simvastatinTABLET;ORAL021687-003Jul 23, 2004ABRXYesNo► Subscribe► SubscribeY► Subscribe
Msd IntlVYTORINezetimibe; simvastatinTABLET;ORAL021687-004Jul 23, 2004ABRXYesYes► Subscribe► SubscribeY► Subscribe
Msd Intl GmbhZETIAezetimibeTABLET;ORAL021445-001Oct 25, 2002ABRXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: RE42461

PCT Information
PCT FiledSeptember 14, 1994PCT Application Number:PCT/US94/10099
PCT Publication Date:March 30, 1995PCT Publication Number: WO95/08532

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Fish and Richardson
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: